1. Introduction {#sec1-molecules-24-04355}
===============

The matrix metalloproteinase (MMP) family of enzymes has been implicated in a great variety of diseases \[[@B1-molecules-24-04355],[@B2-molecules-24-04355],[@B3-molecules-24-04355],[@B4-molecules-24-04355],[@B5-molecules-24-04355],[@B6-molecules-24-04355]\], resulting in the pursuit of MMP inhibitors that has spanned decades \[[@B1-molecules-24-04355],[@B7-molecules-24-04355],[@B8-molecules-24-04355],[@B9-molecules-24-04355],[@B10-molecules-24-04355],[@B11-molecules-24-04355],[@B12-molecules-24-04355]\]. A variety of phosphorus-based peptides have been developed as MMP inhibitors \[[@B7-molecules-24-04355],[@B13-molecules-24-04355],[@B14-molecules-24-04355]\]. Phosphinates/phosphinic peptides contain a hydrolytically stable, tetrahedral phosphinic pseudo-dipeptide moiety which mimics the tetrahedral intermediate formed during Zn^2+^ metalloproteinase-catalyzed amide bond hydrolysis. We have reported that phosphinic triple-helical peptides (THPs) behave as effective transition state analog inhibitors of collagenolytic MMPs \[[@B15-molecules-24-04355],[@B16-molecules-24-04355],[@B17-molecules-24-04355],[@B18-molecules-24-04355],[@B19-molecules-24-04355]\]. Recently, the triple-helical peptide inhibitor (THPI) (Gly-Pro-Hyp)~4~-Gly-mep-Flp-Gly-Pro-Gln-{GlyΨ(PO~2~H-CH~2~)Ile}-His-Lys-Gln-Arg-Gly-Val-Arg-Gly-mep-Flp-(Gly-Pro-Hyp)~4~-Tyr-NH~2~ (designated GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI) (where mep = (*2S,4R*)-4-methylproline, Flp = (*2S,4R*)-4-fluoroproline, and Hyp = 4-hydroxy-[l]{.smallcaps}-proline) was shown to inhibit MMP-8 in the nanomolar range while being a much weaker inhibitor of MT1-MMP \[[@B19-molecules-24-04355]\]. Gene ablation studies have indicated that MMP-8 facilitates sepsis in animal models, while MT1-MMP is protective \[[@B19-molecules-24-04355],[@B20-molecules-24-04355],[@B21-molecules-24-04355]\]. GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI was thus applied in an animal model of sepsis \[[@B19-molecules-24-04355]\]. Using the cecal ligation and puncture (CLP) sepsis model, 70% of the wild-type mice treated with GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI survived after 7 days, while none of the non-treated wild-type mice did \[[@B19-molecules-24-04355]\].

Genetically modified (knockout) mice have been utilized to delineate the roles of MMPs in normal physiological function and pathological states. To examine the specificity of the GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI, *Mmp8* null mice underwent CLP and were then either treated with the THPI or not treated. A survival advantage during sepsis was observed for *Mmp8* null mice compared with wild-type mice \[[@B19-molecules-24-04355]\]. Survival of THPI-treated wild-type mice mirrored that of non-treated *Mmp8* null mice, while survival of *Mmp8* null mice was not augmented by inhibitor treatment \[[@B19-molecules-24-04355]\]. Thus, in consideration of the *Mmp8* null mice data, the GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI was deemed as acting specifically towards MMP-8 in vivo.

The identification of passenger mutations that can accompany MMP knockouts has raised serious concerns as to the interpretation of results from disease models in which MMPs were implicated \[[@B22-molecules-24-04355]\]. For example, *Mmp7*, *Mmp8*, or *Mmp13* null mice were found to be protected from lipopolysaccharide (LPS) lethality (septic shock) \[[@B23-molecules-24-04355],[@B24-molecules-24-04355],[@B25-molecules-24-04355]\]. However, these knockout mice carried a passenger mutation that inactivated *Casp11* (the mouse ortholog of human *Casp4* and *Casp5*) \[[@B22-molecules-24-04355]\]. Caspase-11 has been demonstrated to participate in LPS-induced endotoxic shock and subsequent lethality \[[@B26-molecules-24-04355],[@B27-molecules-24-04355]\]. Mice possessing a non-functional caspase-11 are more resistant to LPS-induced septic shock \[[@B28-molecules-24-04355]\], and the passenger mutation of *Casp11* resulted in mice resistant to LPS-induced endotoxic shock \[[@B22-molecules-24-04355],[@B29-molecules-24-04355]\].

In the above example, the results from MMP-8 knockout mice appear to be validated through the use of a THPI which targeted the MMP of interest (MMP-8) in wild-type mice, as the same phenotype was observed for the CLP knockout mice and the CLP wild type mice treated with the GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI. However, if the applied THPI non-specifically inhibited other enzymes, interpretation of the results becomes ambiguous. Given that the *Mmp8* null mice may have had a *Casp11* inactivating mutation \[[@B22-molecules-24-04355]\], the mirroring of survival in the *Mmp8* null mice by the inhibitor treated wild-type mice could have been the result of the THPI inhibiting caspase-11 in the wild-type mice. MMP inhibitors are not anticipated to inhibit caspase-11, due to the different active site chemistries and sequence specificities \[[@B30-molecules-24-04355],[@B31-molecules-24-04355],[@B32-molecules-24-04355],[@B33-molecules-24-04355],[@B34-molecules-24-04355]\]. However, recent research has indicated that caspase-11 recognition of substrates can be strongly influenced by motifs outside of the active site \[[@B34-molecules-24-04355]\], and thus, there is a possibility of non-specific inhibition by MMP inhibitors whose structures may be complimentary to caspase-11 motifs. In addition, MMP inhibitors that are designed to interact with the active site Zn^2+^ can inhibit non-MMP activity by non-selective metal binding \[[@B35-molecules-24-04355],[@B36-molecules-24-04355]\]. The present study has examined the inhibition of (a) caspase-11 by two phosphinate-based THPIs and (b) other collagenolytic MMPs by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI.

2. Results {#sec2-molecules-24-04355}
==========

Caspase-11 hydrolysis of acetyl-Trp-Glu-His-Asp-pNA was examined at several enzyme and substrate concentrations to obtain conditions under which enzyme inhibition could be studied. It was ultimately determined that 3 U/μL (1.08 μM) caspase-11 and 250 μM acetyl-Trp-Glu-His-Asp-pNA provided a reasonably linear rate of hydrolysis over 15 min. Acetyl-Leu-Glu-Val-Asp-CHO was incubated with caspase-11 at a concentration of 5 μM for 2 h prior to the addition of substrate, and was found to completely inhibit enzymatic activity ([Figure 1](#molecules-24-04355-f001){ref-type="fig"}).

The potential inhibition of caspase-11 by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI was examined by adding 5 μM of the inhibitor to the enzyme for 2 h prior to addition of substrate. A 2 h incubation was utilized based on (a) the generally observed behavior of slow on and off rates for tight-binding inhibitors \[[@B37-molecules-24-04355]\], (b) studies demonstrating that high affinity phosphinate inhibitors of Zn^2+^ metalloproteinases are slow binding \[[@B38-molecules-24-04355]\], and (c) our prior studies using THPIs \[[@B39-molecules-24-04355]\]. This concentration was comparable to that used in our prior CLP mouse model studies (13.5 μM) \[[@B19-molecules-24-04355]\]. No inhibition of caspase-11 activity was observed over 15 min ([Figure 1](#molecules-24-04355-f001){ref-type="fig"}).

A second THPI was examined for inhibitory potential towards caspase-11. (Gly-Pro-Hyp)~4~-Gly-mep-Flp-Gly-Pro-Pro-GlyΨ{PO~2~H-CH~2~}Val-Val-Gly-Glu-Gln-Gly-Glu-Gln-Gly-Pro-Pro-Gly-mep-Flp-(Gly-Pro-Hyp)~4~-NH~2~ (designated α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI) is an effective, and selective, inhibitor of MMP-2 and MMP-9, with K~i~ values of 2.24 and 0.98 nM at 37 °C for MMP-2 and MMP-9, respectively, and exhibiting no or weak (K~i~ = 10--50 μM) inhibition of MMP-1, MMP-3, MMP-8, MMP-13, and MT1-MMP \[[@B15-molecules-24-04355],[@B19-molecules-24-04355]\]. α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI was recently shown to be efficacious in an animal model of multiple sclerosis \[[@B19-molecules-24-04355]\]. 5 μM of α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI was added to the enzyme for 2 h prior to addition of substrate. Approximately 40% inhibition of caspase-11 activity was observed after 15 min ([Figure 2](#molecules-24-04355-f002){ref-type="fig"}). The extent of this inhibition did not increase after 1 h (data not shown). We examined the inhibition of caspase-11 by the α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI using no inhibitor pre-incubation time, and found no inhibition to occur at early time points (data not shown), in similar fashion to what was observed for a 2 h inhibitor pre-incubation ([Figure 2](#molecules-24-04355-f002){ref-type="fig"}).

The inhibitory potency of GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI was initially examined for MMP-1, MMP-3, MMP-8, and MT1-MMP ([Table 1](#molecules-24-04355-t001){ref-type="table"}) \[[@B19-molecules-24-04355]\]. Selectivity within the collagenolytic MMPs was further examined by treating MMP-2, MMP-9, and MMP-13 with GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI. All three enzymes were inhibited by the THPI ([Table 1](#molecules-24-04355-t001){ref-type="table"}). The K~i~ value for MMP-13 was better than that observed for MMP-8 ([Table 1](#molecules-24-04355-t001){ref-type="table"}). MMP-2 and MMP-9 were very efficiently inhibited by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI, with K~i~ values below 10 nM ([Table 1](#molecules-24-04355-t001){ref-type="table"}).

3. Discussion {#sec3-molecules-24-04355}
=============

The *Mmp8* null mice utilized in our CLP study were on a C57BL/6J background \[[@B19-molecules-24-04355]\], which may still harbor the *Casp11* mutation depending upon the extent of backcrossing \[[@B22-molecules-24-04355]\]. The inhibition of caspase-11 by a THPI could occur by two non-exclusive mechanisms: (a) chelation of a caspase-11 metal ion by the THPI phosphinate; and (b) binding of the THPI sequence to a complementary motif on the surface of caspase-11. To consider possibility (a), the mechanism by which caspase-11 contributes to CLP/LPS-induced lethality needs to be taken into account. The CLP sepsis model induces polymicrobial peritonitis and results in translocation of bacteria into the bloodstream (bacteremia) \[[@B40-molecules-24-04355],[@B41-molecules-24-04355]\]. Both Gram negative and Gram positive bacteria enter the bloodstream and tissues, with a shift to Gram negative bacteria with disease progression \[[@B40-molecules-24-04355]\]. Gram negative, but not Gram positive, bacteria activate the caspase-11 non-canonical inflammasome pathway \[[@B28-molecules-24-04355]\]. Caspase-11 directly binds the lipid A tail of LPS via the caspase recruitment domain motif \[[@B28-molecules-24-04355]\]. LPS binding first results in the formation of caspase-11 dimers, followed by auto-hydrolysis at the interdomain linker residue Asp285 \[[@B42-molecules-24-04355]\]. Caspase-11 then undergoes oligomerization, ultimately inducing pyroptosis and secretion of the pro-inflammatory cytokines interleukin-1β and interleukin-18 \[[@B28-molecules-24-04355]\].

MMP inhibitors have an unfortunate history of non-selectivity. Of specific concern is the ability of zinc binding groups to behave in a non-selective fashion. For example, hydroxamic acids have been commonly used in MMP inhibitors, but the ability of hydroxamic acids to non-specifically chelate metal ions, in some cases with greater affinity than zinc, has been noted \[[@B35-molecules-24-04355],[@B36-molecules-24-04355]\]. Caspase-11 is a Cys protease, and it is not anticipated that non-selective metal chelation would be a concern as caspase family members caspase-1, caspase-2, caspase-3, caspase-7, caspase-8, and caspase-9 do not possess structural metals \[[@B43-molecules-24-04355],[@B44-molecules-24-04355]\]. However, the human orthologs of caspase-11, caspase-4 and caspase-5, have been reported to each have one Mg^2+^ ion present (<https://swissmodel.expasy.org/repository/uniprot/P49662> and <https://swissmodel.expasy.org/repository/uniprot/P51878>). Homology modeling indicated that in caspase-4 the Mg^2+^ binds to His338 of the A chain, His338 of the B chain, and Tyr370 of the B chain, while in caspase-5, the Mg^2+^ binds to His395 of the A chain and Glu398 of the B chain. Thus, the Mg^2+^ ion could stabilize caspase-11 dimers, and dimerization is an important step in the caspase-11 pathway contributing to endotoxic shock (see above). As indicated by studies with nucleic acids, phosphates will readily bind Mg^2+^ \[[@B45-molecules-24-04355],[@B46-molecules-24-04355]\]. The GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI did not show inhibition of caspase-11, and thus, Mg^2+^ ions most likely do not undergo non-specific chelation by THPIs (see above).

In consideration of mechanism (b), THPIs have extended sequences that interact with regions well outside of the active site in MMPs \[[@B16-molecules-24-04355],[@B17-molecules-24-04355]\]. These regions of interaction are referred to as secondary binding sites (exosites). The THPI extended sequences could interact with caspase-11 exosites. It has been proposed that caspase-11 substrate specificity is governed by exosite interactions, as the substrate preferences of caspase-11 cannot be explained by the sequences at the active site \[[@B34-molecules-24-04355]\]. One possibility is that negatively charged residues in the P~7~-P~10~ region may be unfavorable for substrate interaction with caspase-11 \[[@B34-molecules-24-04355]\]. GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI possesses no negative charges, and thus could interact with caspase-11. However, as this THPI did not inhibit caspase-11, we can assume that there is no exosite interaction.

It is interesting to note that α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI exhibited some inhibition of caspase-11 activity, although it occurred at a relatively high inhibitor concentration (5 μM). It is not likely that this inhibition was due to Mg^2+^ chelation (based on the lack of caspase-11 inhibition by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI). This suggests a possible interaction between α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI and a caspase-11 allosteric site, although α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI possesses 6 negatively charged residues, which are not favored in the P~7~-P~10~ region by caspase-11 (see above).

There are two caveats to the interpretation of results from the present study. First, the caspase-11 substrate used here is small (4 amino acids), whereas in the CLP/LPS animal models caspase-11 is processing proteins. An exosite-binding inhibitor might not impact caspase-11 hydrolysis of a small substrate but could impact processing of a protein, unless binding to the exosite had an allosteric effect on the enzyme. Second, chelation of Mg^2+^ ions might not impact caspase-11 activity towards a small substrate, but rather inhibit dimerization of the enzyme. Dimerization might be required to facilitate specific proteolytic activities in CLP/LPS models (see above).

We presently observed that GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI did not inhibit caspase-11 activity. This result supports our prior report on the modulation of sepsis by MMP-8 inhibition, not caspase-11 inhibition \[[@B19-molecules-24-04355]\]. However, our prior studies did not examine the full range of collagenolytic MMPs that might have been inhibited by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI. We found that MMP-2, MMP-9, and MMP-13 are effectively inhibited by the THPI, along with MMP-8. Thus, the observed protection from sepsis in the CLP mouse model by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI may have been due to inhibition of multiple MMPs. The use of more selective inhibitors will elucidate the role of each MMP in sepsis.

4. Materials and Methods {#sec4-molecules-24-04355}
========================

GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI and α1(V)GlyΨ{PO~2~H-CH~2~}Val \[mep~14,32~,Flp~15,33~\] THPI were synthesized and characterized as described previously \[[@B19-molecules-24-04355]\]. Recombinant caspase-11 (residues 81-373), caspase substrate acetyl-Trp-Glu-His-Asp-pNA (where pNA = *p*-nitroaniline) (MW 747.8 Da), and caspase-4 and caspase-5 inhibitor acetyl-Leu-Glu-Val-Asp-CHO (MW 500.6 Da) were obtained from Enzo Life Sciences, Inc.

4.1. Caspase Enzyme Assay {#sec4dot1-molecules-24-04355}
-------------------------

Caspase-11 (9 U/μL in 10 μL caspase activity buffer (100 mM 2-(*N*-morpholino)ethanesulfonic acid (MES)), pH 6.5, 0.1% 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate (CHAPS), 10% poly(ethylene-glycol) (PEG)-8000, 10 mM dithiothreitol (DTT)) was added to 10 μL of caspase-11 inhibitor (5 μM), THPI (5 μM), or no inhibitor in caspase activity buffer. For testing THPIs as inhibitors, enzyme was incubated with THPIs for 2 h at 37 °C. Residual enzyme activity was monitored by adding 10 μL of caspase substrate in caspase activity buffer to produce a final concentration of \<0.1K~M~. pNA cleavage from the peptide was monitored at 37 °C over 1 h using λ = 405 nm on a Bio-Tek Synergy H1 Reader or H4 Hybrid Reader.

4.2. Matrix Metalloproteinases (MMPs) {#sec4dot2-molecules-24-04355}
-------------------------------------

Human recombinant, full-length proMMP-8 and proMMP-13 were purchased from R&D Systems (Minneapolis, MN, USA) and activated according to the manufacturer's instructions prior to use. *p*-Aminophenylmercuric acetate was purchased from EMD Biosciences (San Diego, CA, USA), and trypsin (TPCK-treated) was purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA). Recombinant MMP-2 and MMP-9 catalytic domain were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used directly without further activation in the desired concentration.

ProMMP-8 and proMMP-13 were activated by mixing an equal volume of stock enzyme solution and activator (*p*-aminomercuric acetate to a final concentration of 1 m[m]{.smallcaps}) followed by 2-3 h incubation in a 37 °C water bath. Activated MMPs were diluted to 200-400 n[m]{.smallcaps} in ice cold TSB\*Zn (50 m[m]{.smallcaps} Tris, 100 m[m]{.smallcaps} NaCl, 10 m[m]{.smallcaps} CaCl~2~, 0.05% Brij-35, 0.02% NaN~3~, 1 μ[m]{.smallcaps} ZnCl~2~, pH 7.5) to prevent autoproteolysis. Enzyme aliquots were either kept on wet ice and used the same day or immediately frozen at −80 °C. MMP activity was initially evaluated by using the Knight substrate (Mca-Lys-Pro-Leu-Gly-Leu-Lys-(Dnp)-Ala-Arg-NH~2~, where Mca = 7-methoxycoumarin-4-acetyl and Dnp = 2,4-dinitrophenyl) and compared with prior data \[[@B16-molecules-24-04355],[@B17-molecules-24-04355]\]. In this way, activity towards the substrate was used as an indicator of enzyme integrity, rather than TIMP titration, as performed previously \[[@B47-molecules-24-04355]\].

4.3. Inhibition Kinetic Studies {#sec4dot3-molecules-24-04355}
-------------------------------

Peptide substrate and THPI solutions were prepared using TSB\*Zn. 1--10 nM enzyme was incubated with varying concentration of inhibitor for 2 h at 37 °C. Residual enzyme activity was monitored by adding Knight substrate solution in TSB\*Zn to produce a final concentration of \<0.1K~M~. Initial velocity rates were determined from the first 10 min of hydrolysis when product release is linear with time. Fluorescence was measured on a Bio-Tek Synergy H1 Reader or H4 Hybrid Reader using λ~excitation~ = 324 nm and λ~emission~ = 393 nm. Apparent K~i~ values were calculated from the following formulas \[[@B15-molecules-24-04355]\]: where *I*~t~ is the total inhibitor concentration, *E*~t~ is the total enzyme concentration, *A*~t~ is the total substrate concentration, *v*~o~ is the activity in the absence of inhibitor, and K~M~ is the Michaelis constant. In our assays the value of *E*~t~/K~i~^(app)^ does not exceed 100 so that the inhibitor is distributed in both free and bound forms, and K~i~^(app)^ can be calculated by fitting inhibition data to equation 1. Because the substrate concentration is less than K~M~/10, K~i~^(app)^ values are insignificantly different from true K~i~ values. In cases where weak inhibition occurred, K~i~^(app)^ values were calculated using Prism 7.0 (GraphPad, San Diego, CA, USA) by fitting data to the equation *v*~i~ = *v*~o~/(1 + *I*~t~/ K~i~^(app)^).
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Inhibition of matrix metalloproteinases (MMPs) by GlyΨ{PO~2~H-CH~2~}Ile-His-Lys-Gln THPI at 37 °C.

  Enzyme    K~i~ (nM)
  --------- ------------------
  MT1-MMP   4704 ± 708.4 ^1^
  MMP-8     124.6 ± 6.9 ^1^
  MMP-8     378.1 ± 40.6
  MMP-1     169.2 ± 28.4 ^1^
  MMP-3     NI ^1,2^
  MMP-2     2.2 ± 0.20
  MMP-9     3.7 ± 0.40
  MMP-13    31.7 ± 7.6

^1^ Previously reported \[[@B19-molecules-24-04355]\]. ^2^ NI = No inhibition at a triple-helical peptide inhibitor (THPI) concentration of 1000 nM.
